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Abstract 22 
Recently, a comparison of estimated tobramycin exposure (AUC0-24) using Bayesian 23 
forecasting (BF) versus true exposure demonstrated accuracy in patients with cystic fibrosis.  24 
Theoretically, when using BF methods the predictive performance towards estimating an 25 
individual’s exposure should improve with additional observations; however, there is limited 26 
applicable evidence against true exposure. We demonstrate that with additional data from 27 
previous dosing intervals, predicted performance to estimate exposure improves. 28 
Letter 29 
A comparison of estimated tobramycin exposure (area under the concentration-time 30 
curve (AUC0-24)) using Bayesian forecasting (BF) to true measured exposure demonstrated 31 
accuracy in adult patients with cystic fibrosis (1). Clinical practice relies on two blood 32 
samples to estimate drug exposure; however, BF has the potential to estimate AUC0-24 using 33 
one concentration, which would be more practical and cost effective. Theoretically, when 34 
using BF methods the predictive performance towards estimating an individual’s exposure 35 
should improve with additional observations (2, 3) however, there is limited applicable 36 
evidence (4), particularly against true exposure.  37 
Rich (8 samples/patient) sampling data were available to calculate true exposure over 38 
one dosing interval (“study day”) and reported by Barras et al. (1). Further, a minimum of 39 
two additional concentrations (range 2 to 6) were available per patient from previous doses 40 
(Table 1); taken at 100 and 520 mins post-dose, prior to the study day. Here, we investigated 41 
changes in predictive performance of BF when these additional tobramycin concentrations 42 
supported exposure estimation. Previous methods were applied (1) using TDMx software (5), 43 
with the addition of a complete dosing and sampling history prior to the study day in the BF 44 
program. Tobramycin AUC0-24 were estimated for the study day using, as previously, one 45 
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(100 mins post-dose) and then two (100 and 520 mins post-dose) and compared to true 46 
exposure (1). Relative prediction errors (RE (%)); relative difference between true exposure 47 
and estimated exposure, standardised to the true exposure; were calculated (Table 1 and FIG 48 
1).  49 
Twelve patients contributed 48 additional concentrations; resulting in 24 newly 50 
estimated tobramycin AUC0-24. Average predictive performance improved when additional 51 
data was included, using either one concentration (RE from 3.9% to 1.4%) or two 52 
concentrations (RE from 1.0% to 0.3%) compared to not including previous dosing data. For 53 
both methods the average predictive performance was low (<5%) suggesting that both are 54 
suitable to predict exposure.  55 
On an individual level, the RE improved for six patients and for six patients the REs 56 
declined (Table 1). Originally, REs for 10 patients were below +/-20%, of these 3 had RE’s 57 
within +/-5%. After adding data 9 patients had REs below +/-20% of which 4 had RE’s 58 
within +/-5% of the truth. FIG 1 shows two outlier points where RE increased from -5.8% to 59 
-51.9% and -1.9% to -45.6%. We suspect this is due to erroneous non-study day data, which 60 
is subject to standard clinical care. BF is a probability-based approach for dose 61 
individualisation, and as such when using sparse data, the fit may not be optimised towards 62 
the individual, but rather the population average, accounting for greater data uncertainty (6, 7, 63 
8). While within patient variability (WPV) from dose to dose was expected to be low (9), the 64 
weighting of ‘older’ data in BF requires further research. These details should be considered 65 
alongside the clinical situation of the patient before making dosing decisions.   66 
We recognise limitations to this study, particularly the small sample size, however the 67 
study is hypothesis generating. An advantage of the BF method is that it helps identify data 68 
that may be associated with uncertainty. Today in clinical practice, substantially varying data 69 
(>+/-20%) from one day to the next are already treated suspiciously and would initiate re-70 
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sampling. The development of an algorithm, which objectively assesses whether inclusion or 71 
exclusion of data from other dosing intervals, would be justified. In addition, true outlying 72 
patients may be recognised better using non-parametric BF (10) compared to parametric BF. 73 
We did not assess other exposure metrics (e.g. Cmax, Cmin) as these points were not observed, 74 
however a benefit of BF is that sampling at these times is not essential to predict the 75 
exposure, e.g. also to avoid toxicity.  76 
On average, with additional data from previous dosing intervals, predicted 77 
performance to estimate AUC0-24 improved, however as shown by two outliners non-study 78 
day data may also increase uncertainty. Overall, we recommend using all available dosing 79 
and concentration data, if they can be considered reliable, for increased accuracy in exposure 80 
prediction and the understanding of uncertainty associated with concentration measurements 81 
when using the BF method.  82 
 83 
 84 
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Table 1 Summary of tobramycin AUC0-24 (mg/liter∙h) and relative prediction errors (%) for each patient using data from the study day and all 85 
additional observations and dosing data prior to the study day from the same admission.  86 
 87 
AUC, Area under the concentration-time curve (mg/liter∙h); AUCtrue, AUC measured using trapezoidal rule (mg/liter∙h); AUC1, AUC estimated 88 
using one concentration (100 mins post dose) (mg/liter∙h); AUC2, AUC estimated using two samples (100 and 520 mins post dose) (mg/liter∙h); 89 
AUC1
previous data
, AUC estimated using one concentration (100 mins post dose) with additional tobramycin concentration from the same 90 
admission (mg/liter∙h); AUC2
previous data
, AUC estimated using two samples (100 and 520 mins post dose) with additional tobramycin 91 
Patient 
ID 
Trapezoidal 
method  AUC1 AUC2 
AUC1
previous 
data
 
AUC2
previous 
data
 
Number 
of 
previous 
doses  
Number of 
previous 
observations 
(doses with 
observations) RE1 % RE2  % 
RE1
previous 
data
   % 
RE2
previous 
data
   % 
                
 1 88.9 86.8 92.9 74.7 76.2 5 6 (3) 2.4% -4.5% 16.0% 14.3% 
2 94.9 107.6 105.3 90.8 98.6 5 4 (2) -13.4% -11.0% 4.3% -3.9% 
3 71.9 76.1 73.3 109.2 104.7 3 2 (1) -5.8% -1.9% -51.9% -45.6% 
4 79.3 68.7 70.5 80.7 83.7 3 2 (1) 13.4% 11.1% -1.8% -5.5% 
5 79.8 69 78.6 74.3 74.2 5 6 (3) 13.5% 1.5% 6.9% 7.0% 
6 81.5 74.6 78.4 71 71 5 6 (3) 8.5% 3.8% 12.9% 12.9% 
7 71.9 65.2 70 82.3 81.1 6 4 (2) 9.3% 2.6% -14.5% -12.8% 
8 102.4 87.9 99.4 67.8 71.5 4 6 (3) 14.2% 2.9% 33.8% 30.2% 
9 102.8 87.8 91.4 79.5 83.6 6 2 (1) 14.6% 11.1% 22.7% 18.7% 
10 62.7 56.1 55.3 66.7 64 5 2 (1) 10.5% 11.8% -6.4% -2.1% 
11 77.6 77.6 80.3 74.7 76.1 6 4 (2) 0.0% -3.5% 3.7% 1.9% 
12 51.1 61.4 57.1 55.5 56.9 5 4 (2) -20.2% -11.7% -8.6% -11.4% 
Average                3.9% 1.0% 1.4% 0.3% 
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concentration from the same admission (mg/liter∙h); RE1, relative prediction error using one concentration (100 mins post dose) (%); RE2, 92 
relative prediction error using two concentrations (100 and 520 mins post dose) (%); RE1
previous data
, relative prediction error using one 93 
concentration (100 mins post dose) with additional tobramycin concentration from the same admission (%); RE2
previous data
, relative prediction 94 
error using two samples (100 and 520 mins post dose) with additional tobramycin concentration from the same admission (%) 95 
 96 
 97 
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 99 
 100 
 101 
FIG 1 Box plot of relative prediction error (%) when comparing true measured exposure 102 
(AUC) with estimated exposure using Bayesian forecasting  103 
 104 
AUC, Area under the concentration-time curve; AUC1, AUC estimated using one 105 
concentration measured on the study day (100 mins post-dose); AUC2, AUC estimated using 106 
two concentrations measured on the study day (sampled at 100 and 560 mins post-dose); 107 
AUC1
previous data
, AUC estimated using one concentration measured on the study day (100 108 
mins post dose) and additional tobramycin concentrations from previous dose within the 109 
same admission; AUC2
previous data
, AUC estimated using two concentrations measured on the 110 
study day (100 and 560 mins post-dose) and additional tobramycin concentrations from 111 
previous dose within the same admission  112 
 113 
 114 
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